Skip to content
NACE Rev. 2 21.10 Legacy Rev. 2 21.1 ↗
● Official Registry Data: 2026-11-19

21.10 — Manufacture of basic pharmaceutical products

NACE Rev. 2 21.10 (Manufacture of basic pharmaceutical products) classifies within economic division 21 (Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization), linking EU/UN activity boundaries with US NAICS, UK SIC, and national regulatory obligations.

01 / Standard & Revision
NACE Rev. 2

Eurostat • v2.0

02 / Parent Hierarchy
21.1

Manufacture of basic pharmaceutical products

03 / Mapped Standards
8

NAICS 325199 • SIC 21100

04 / Subclasses & Scope
2 Items

MCC 5122

01 / OFFICIAL SCOPE & OPERATORS

Activity Scope, Operators & Exclusions

Who Uses This Code & Typical Business Models

  • Active pharmaceutical ingredient (API) and finished drug makers
  • Vaccine, biologic, serum, and diagnostic preparation labs
  • Veterinary medicine and medicated surgical dressing manufacturers

This Class Includes

2
  • manufacture of medicinal active substances to be used for their pharmacological properties in the manufacture of medicaments: antibiotics, basic vitamins, salicylic and O-acetylsalicylic acids etc.
  • processing of blood

Also Includes

  • manufacture of chemically pure sugars
  • processing of glands and manufacture of extracts of glands etc.

This Class Excludes (Cross-References)

0

—

02 / REGULATORY & TAX DOSSIER

Legislation, Licensing, Incorporation & Tax Framework

Div. 21 • Sec. C Law 6948 Industrial Reg.

Governing Statutes & Regulations

Pharmaceutical Preparations Law No. 1262 EU-harmonized Pharmaceutical GMP Regulation Drug Marketing Authorization Reg. Industrial Registry Law No. 6948

Mandatory Permits, Licenses & Authorities

  • TİTCK Manufacturing Authorization, Good Manufacturing Practice (GMP) Certificate, and Drug Marketing Authorizations
  • İTS serialization integration & mandatory Qualified Person (Mesul Müdür)
  • Ministry of Agriculture Veterinary Drug License for 21.20 animal formulations

Incorporation Route & Chamber Registration

EU NACE Rev. 2.1 Framework
Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization.
United States (IRS / SBA / NAICS)
Maps to NAICS 3254. Requires FDA NDA/ANDA/BLA approval, strict 21 CFR 210/211 cGMP inspection, and DSCSA serialization.
United Kingdom (Companies House / HMRC)
Requires MHRA Manufacturer’s Licence (MIA), Marketing Authorisation, and Qualified Person batch release under UK SIC 21xxx.

VAT, Withholding & Statutory Incentives

  • Licensed pharmaceuticals carry 10% reduced VAT in Turkey.
  • Classified as High-Technology Manufacturing: qualifies for KOSGEB Business Dev grants, Law 5746 R&D Center deductions, and Priority/Strategic Investment Incentives.

Cross-Border Regulatory Frameworks (EU / US / UK)

TR • Corporate & Tradesmen Registry

Chamber of Industry / Commerce + Industrial Registry (Capital Company required) — JSC/LLC structure mandatory for GMP pharmaceutical manufacturing.

EU / Global Technical Alignment

Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization.

AUDIT & BOUNDARY CHECK

Classification Boundaries & Audit Risks

  • Dietary supplements and vitamins belong in Div. 10 (10.89) under Food Law, not Div. 21 drugs.
  • Non-medicated medical devices and surgical instruments sit in Div. 32 (32.50).
04 / INTERNATIONAL CROSSWALK & MCC

Global Classification Passport

Verified structural and concordance mappings across EU, US, UK, UN, and national registries.

Payment Processing & ISO 18245 MCC Profile

Visa / Mastercard ISO 18245
MCC 5122
High Risk / Reserve Review
Drugs, Drug Proprietaries and Druggists Sundries

Strictly underwritten: non-OTC pharmaceuticals require pharmacy licensing and Card Brand high-risk registration.

05 / BOUNDARIES & COMPARISON

Critical Distinctions & Sibling Codes

Open Full Comparison Tool →
06 / TAXONOMY TREE

Classification Hierarchy & Data Export

07 / FAQ

Frequently Asked Questions

What business activities and models fall under NACE Rev. 2 21.10?

21.10 (Manufacture of basic pharmaceutical products): manufacture of medicinal active substances to be used for their pharmacological properties in the manufacture of medicaments: antibiotics, basic vitamins, salicylic and O-acetylsalicylic acids etc.; processing of blood. Typical operators: Active pharmaceutical ingredient (API) and finished drug makers; Vaccine, biologic, serum, and diagnostic preparation labs.

What regulatory licensing and tax rules apply to 21.10 across EU, US, UK, or Turkey?

EU: Governed by Directive 2001/83/EC, EMA/National Marketing Authorization, EU GMP Annex 1, and Falsified Medicines serialization. US: Maps to NAICS 3254. Requires FDA NDA/ANDA/BLA approval, strict 21 CFR 210/211 cGMP inspection, and DSCSA serialization. UK: Requires MHRA Manufacturer’s Licence (MIA), Marketing Authorisation, and Qualified Person batch release under UK SIC 21xxx.

What are the international classification equivalents and MCC code for 21.10?

Verified concordance for 21.10: US NAICS 2022: 325199 (All Other Basic Organic Chemical Manufacturing), 325411 (Medicinal and Botanical Manufacturing), 325412 (Pharmaceutical Preparation Manufacturing) • UK SIC 2007: 21100 (Manufacture of basic pharmaceutical products) • Payment MCC 5122 (Drugs, Drug Proprietaries and Druggists Sundries).

What replaces legacy NACE Rev. 2 code 21.10 in NACE Rev. 2.1?

In the 2025–2026 NACE Rev. 2.1 revision, 21.10 transitions to 21.10 (Manufacture of basic pharmaceutical products).